Comparison of rizatriptan and other triptans on stringent measures of efficacy

J. U. Adelman, Richard B. Lipton, M. D. Ferrari, H. C. Diener, K. A. McCarroll, K. Vandormael, C. R. Lines

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective: To compare the efficacy of oral rizatriptan 10 mg with oral doses of sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures. Methods: Retrospective analysis of data from five randomized, placebo-controlled, double-masked clinical trials in which oral rizatriptan was directly compared with oral sumatriptan 100 mg (n = 772), 50 mg (n = 1116), 25 mg (n = 1183), naratriptan 2.5 mg (n = 413), and zolmitriptan 2.5 mg (n = 580) for the acute treatment of a moderate or severe migraine attack. Outcome measures: Percentage of patients pain-free at 2 hours, symptom-free at 2 hours (no pain, nausea, photophobia, phonophobia, vomiting, or functional disability), 24-hour sustained pain-free (no headache at 2 hours, no recurrence, and no additional antimigraine medications for 24 hours). Results: More patients taking rizatriptan 10 mg were pain-free at 2 hours than were patients taking sumatriptan 100 mg (40% vs 33%, p = 0.019), sumatriptan 50 mg (40% vs 35%, p = 0.009), sumatriptan 25 mg (38% vs 27%, p < 0.001), naratriptan 2.5 mg (45% vs 21%, p < 0.001), and zolmitriptan 2.5 mg (43% vs 36%, p = 0.041). More patients taking rizatriptan 10 mg were symptom-free at 2 hours than were patients taking sumatriptan 100 mg (31% vs 22%, p = 0.002), sumatriptan 50 mg (33% vs 28%, p = 0.003), sumatriptan 25 mg (33% vs 24%, p < 0.001), naratriptan 2.5 mg (30% vs 11%, p < 0.001), and zolmitriptan 2.5 mg (31% vs 24%, p = 0.042). More patients taking rizatriptan 10 mg had a 24-hour sustained pain-free response than did patients taking sumatriptan 100 mg (27% vs 23%, p = 0.112), sumatriptan 50 mg (30% vs 26%, p = 0.015), sumatriptan 25 mg (27% vs 20%, p = 0.005), naratriptan 2.5 mg (29% vs 17%, p = 0.004), and zolmitriptan 2.5 mg (32% vs 24%, p = 0.013). Conclusion: Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response.

Original languageEnglish (US)
Pages (from-to)1377-1383
Number of pages7
JournalNeurology
Volume57
Issue number8
StatePublished - Oct 23 2001

Fingerprint

Tryptamines
Sumatriptan
zolmitriptan
Outcome Assessment (Health Care)
rizatriptan
Hyperacusis
Photophobia
Migraine Disorders
Nausea
Vomiting
Headache
Pain-Free
naratriptan

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Adelman, J. U., Lipton, R. B., Ferrari, M. D., Diener, H. C., McCarroll, K. A., Vandormael, K., & Lines, C. R. (2001). Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology, 57(8), 1377-1383.

Comparison of rizatriptan and other triptans on stringent measures of efficacy. / Adelman, J. U.; Lipton, Richard B.; Ferrari, M. D.; Diener, H. C.; McCarroll, K. A.; Vandormael, K.; Lines, C. R.

In: Neurology, Vol. 57, No. 8, 23.10.2001, p. 1377-1383.

Research output: Contribution to journalArticle

Adelman, JU, Lipton, RB, Ferrari, MD, Diener, HC, McCarroll, KA, Vandormael, K & Lines, CR 2001, 'Comparison of rizatriptan and other triptans on stringent measures of efficacy', Neurology, vol. 57, no. 8, pp. 1377-1383.
Adelman JU, Lipton RB, Ferrari MD, Diener HC, McCarroll KA, Vandormael K et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology. 2001 Oct 23;57(8):1377-1383.
Adelman, J. U. ; Lipton, Richard B. ; Ferrari, M. D. ; Diener, H. C. ; McCarroll, K. A. ; Vandormael, K. ; Lines, C. R. / Comparison of rizatriptan and other triptans on stringent measures of efficacy. In: Neurology. 2001 ; Vol. 57, No. 8. pp. 1377-1383.
@article{84bfb41c86a2445d8a93c6560daf5453,
title = "Comparison of rizatriptan and other triptans on stringent measures of efficacy",
abstract = "Objective: To compare the efficacy of oral rizatriptan 10 mg with oral doses of sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures. Methods: Retrospective analysis of data from five randomized, placebo-controlled, double-masked clinical trials in which oral rizatriptan was directly compared with oral sumatriptan 100 mg (n = 772), 50 mg (n = 1116), 25 mg (n = 1183), naratriptan 2.5 mg (n = 413), and zolmitriptan 2.5 mg (n = 580) for the acute treatment of a moderate or severe migraine attack. Outcome measures: Percentage of patients pain-free at 2 hours, symptom-free at 2 hours (no pain, nausea, photophobia, phonophobia, vomiting, or functional disability), 24-hour sustained pain-free (no headache at 2 hours, no recurrence, and no additional antimigraine medications for 24 hours). Results: More patients taking rizatriptan 10 mg were pain-free at 2 hours than were patients taking sumatriptan 100 mg (40{\%} vs 33{\%}, p = 0.019), sumatriptan 50 mg (40{\%} vs 35{\%}, p = 0.009), sumatriptan 25 mg (38{\%} vs 27{\%}, p < 0.001), naratriptan 2.5 mg (45{\%} vs 21{\%}, p < 0.001), and zolmitriptan 2.5 mg (43{\%} vs 36{\%}, p = 0.041). More patients taking rizatriptan 10 mg were symptom-free at 2 hours than were patients taking sumatriptan 100 mg (31{\%} vs 22{\%}, p = 0.002), sumatriptan 50 mg (33{\%} vs 28{\%}, p = 0.003), sumatriptan 25 mg (33{\%} vs 24{\%}, p < 0.001), naratriptan 2.5 mg (30{\%} vs 11{\%}, p < 0.001), and zolmitriptan 2.5 mg (31{\%} vs 24{\%}, p = 0.042). More patients taking rizatriptan 10 mg had a 24-hour sustained pain-free response than did patients taking sumatriptan 100 mg (27{\%} vs 23{\%}, p = 0.112), sumatriptan 50 mg (30{\%} vs 26{\%}, p = 0.015), sumatriptan 25 mg (27{\%} vs 20{\%}, p = 0.005), naratriptan 2.5 mg (29{\%} vs 17{\%}, p = 0.004), and zolmitriptan 2.5 mg (32{\%} vs 24{\%}, p = 0.013). Conclusion: Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response.",
author = "Adelman, {J. U.} and Lipton, {Richard B.} and Ferrari, {M. D.} and Diener, {H. C.} and McCarroll, {K. A.} and K. Vandormael and Lines, {C. R.}",
year = "2001",
month = "10",
day = "23",
language = "English (US)",
volume = "57",
pages = "1377--1383",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Comparison of rizatriptan and other triptans on stringent measures of efficacy

AU - Adelman, J. U.

AU - Lipton, Richard B.

AU - Ferrari, M. D.

AU - Diener, H. C.

AU - McCarroll, K. A.

AU - Vandormael, K.

AU - Lines, C. R.

PY - 2001/10/23

Y1 - 2001/10/23

N2 - Objective: To compare the efficacy of oral rizatriptan 10 mg with oral doses of sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures. Methods: Retrospective analysis of data from five randomized, placebo-controlled, double-masked clinical trials in which oral rizatriptan was directly compared with oral sumatriptan 100 mg (n = 772), 50 mg (n = 1116), 25 mg (n = 1183), naratriptan 2.5 mg (n = 413), and zolmitriptan 2.5 mg (n = 580) for the acute treatment of a moderate or severe migraine attack. Outcome measures: Percentage of patients pain-free at 2 hours, symptom-free at 2 hours (no pain, nausea, photophobia, phonophobia, vomiting, or functional disability), 24-hour sustained pain-free (no headache at 2 hours, no recurrence, and no additional antimigraine medications for 24 hours). Results: More patients taking rizatriptan 10 mg were pain-free at 2 hours than were patients taking sumatriptan 100 mg (40% vs 33%, p = 0.019), sumatriptan 50 mg (40% vs 35%, p = 0.009), sumatriptan 25 mg (38% vs 27%, p < 0.001), naratriptan 2.5 mg (45% vs 21%, p < 0.001), and zolmitriptan 2.5 mg (43% vs 36%, p = 0.041). More patients taking rizatriptan 10 mg were symptom-free at 2 hours than were patients taking sumatriptan 100 mg (31% vs 22%, p = 0.002), sumatriptan 50 mg (33% vs 28%, p = 0.003), sumatriptan 25 mg (33% vs 24%, p < 0.001), naratriptan 2.5 mg (30% vs 11%, p < 0.001), and zolmitriptan 2.5 mg (31% vs 24%, p = 0.042). More patients taking rizatriptan 10 mg had a 24-hour sustained pain-free response than did patients taking sumatriptan 100 mg (27% vs 23%, p = 0.112), sumatriptan 50 mg (30% vs 26%, p = 0.015), sumatriptan 25 mg (27% vs 20%, p = 0.005), naratriptan 2.5 mg (29% vs 17%, p = 0.004), and zolmitriptan 2.5 mg (32% vs 24%, p = 0.013). Conclusion: Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response.

AB - Objective: To compare the efficacy of oral rizatriptan 10 mg with oral doses of sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures. Methods: Retrospective analysis of data from five randomized, placebo-controlled, double-masked clinical trials in which oral rizatriptan was directly compared with oral sumatriptan 100 mg (n = 772), 50 mg (n = 1116), 25 mg (n = 1183), naratriptan 2.5 mg (n = 413), and zolmitriptan 2.5 mg (n = 580) for the acute treatment of a moderate or severe migraine attack. Outcome measures: Percentage of patients pain-free at 2 hours, symptom-free at 2 hours (no pain, nausea, photophobia, phonophobia, vomiting, or functional disability), 24-hour sustained pain-free (no headache at 2 hours, no recurrence, and no additional antimigraine medications for 24 hours). Results: More patients taking rizatriptan 10 mg were pain-free at 2 hours than were patients taking sumatriptan 100 mg (40% vs 33%, p = 0.019), sumatriptan 50 mg (40% vs 35%, p = 0.009), sumatriptan 25 mg (38% vs 27%, p < 0.001), naratriptan 2.5 mg (45% vs 21%, p < 0.001), and zolmitriptan 2.5 mg (43% vs 36%, p = 0.041). More patients taking rizatriptan 10 mg were symptom-free at 2 hours than were patients taking sumatriptan 100 mg (31% vs 22%, p = 0.002), sumatriptan 50 mg (33% vs 28%, p = 0.003), sumatriptan 25 mg (33% vs 24%, p < 0.001), naratriptan 2.5 mg (30% vs 11%, p < 0.001), and zolmitriptan 2.5 mg (31% vs 24%, p = 0.042). More patients taking rizatriptan 10 mg had a 24-hour sustained pain-free response than did patients taking sumatriptan 100 mg (27% vs 23%, p = 0.112), sumatriptan 50 mg (30% vs 26%, p = 0.015), sumatriptan 25 mg (27% vs 20%, p = 0.005), naratriptan 2.5 mg (29% vs 17%, p = 0.004), and zolmitriptan 2.5 mg (32% vs 24%, p = 0.013). Conclusion: Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response.

UR - http://www.scopus.com/inward/record.url?scp=0035940598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035940598&partnerID=8YFLogxK

M3 - Article

C2 - 11673575

AN - SCOPUS:0035940598

VL - 57

SP - 1377

EP - 1383

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -